ProfileGDS5678 / 1416887_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 28% 27% 27% 29% 29% 40% 27% 27% 28% 28% 26% 28% 28% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.743531
GSM967853U87-EV human glioblastoma xenograft - Control 22.6382328
GSM967854U87-EV human glioblastoma xenograft - Control 32.6238727
GSM967855U87-EV human glioblastoma xenograft - Control 42.5788227
GSM967856U87-EV human glioblastoma xenograft - Control 52.6196829
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7434529
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9742940
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6138527
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5988127
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6244228
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6337428
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5781626
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6344528
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6319828